PLA-PRU-PRU-PLA

Phase 2Small molecule

PLA-PRU-PRU-PLA is one of 3 small molecule programs targeting Intestinal Pseudo-Obstruction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal Pseudo-ObstructionActive, not recruiting

Intestinal Pseudo-ObstructionPhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Intestinal Pseudo-Obstruction

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 2

1 2

Velusetrag

TTheravance Biopharma

Phase 2

1 3

PLA-PRU-PRU-PLA

MMovetis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intestinal Pseudo-Obstruction1 trial

Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)

Completed·MMovetis·Phase 2·NCT00793247

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PLA-PRU-PRU-PLA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PLA-PRU-PRU-PLA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PLA-PRU-PRU-PLA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Movetis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMovetis

PLA-PRU-PRU-PLA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intestinal Pseudo-Obstruction1 trial

References

Drug Info

Quick Facts

Related News